反应详情

To a solution of 1-(4-amino-quinazoline-7-ylmethyl)-3-(S)-methoxymethyl-piperazine-2-one, EXAMPLE 75, (50 mg, 0.16 mmol) and 3-cyanocinnamic acid (29 mg, 0.17 mmol, prepared from 3-cyanobenzaldehyde) in 1 mL of DMF is added N,N-diisopropylethylamine (0.07 mL, 0.38 mmol), followed by 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (TBTU) (59 mg, 0.18 mmol). The resulting mixture is stirred at room temperature for 16 h and the solution is concentrated. The crude product is purified by RP-HPLC eluting in a gradient of 10% CH3CN/H2O (0.1% TFA) to 60% CH3CN/H2O (0.1% TFA) over 30 min and the appropriate product fractions are combined and lyopholized to provide the title compound (73 mg, 0.13 mmol) as a white solid. 1H NMR (d6-DMSO, 300 MHz) δ9.72 (bs, 2H), 8.78 (s, 1H), 8.40 (s, 1H), 8.35 (d, 1H), 8.04 (m, 1H), 7.83 (d, 1H), 7.60 (m, 4H), 7.46 (d, 1H), 5.25-4.44 (m, 4H, rotamers), 4.02 (m, 1H), 3.66 (m, 1H), 3.51-3.40 (m, 3H), 3.27 (s, 3H). ISP MS, [M+H]+=457.

1. concentrationthe solution is concentrated
2. customThe crude product is purified by RP-HPLC
3. washeluting in a gradient of 10% CH3CN/H2O (0.1% TFA) to 60% CH3CN/H2O (0.1% TFA) over 30 min